The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts.

IF 2.9 3区医学 Q2 NEUROSCIENCES

Neuroscience Pub Date : 2025-01-18 DOI:10.1016/j.neuroscience.2025.01.040

Hayder M Al-Kuraishy, Ali I Al-Gareeb, Salwa H Zekry, Mubarak Alruwaili, Athanasios Alexiou, Marios Papadakis, Gaber El-Saber Batiha

{"title":"The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts.","authors":"Hayder M Al-Kuraishy, Ali I Al-Gareeb, Salwa H Zekry, Mubarak Alruwaili, Athanasios Alexiou, Marios Papadakis, Gaber El-Saber Batiha","doi":"10.1016/j.neuroscience.2025.01.040","DOIUrl":null,"url":null,"abstract":"<p><p>Cerebrolysin (CBL) is a combination of neurotrophic peptides and amino acids derived from pig brains. CBL can cross the blood-brain barrier (BBB) and its biological effect is similar to the effect of endogenous neurotrophic effects. The mechanism of action of CBL is related to the induction of neurogenesis, neuroplasticity, neuroprotection, and neurotrophicity. Therefore, CBL may be effective against the development and progression of neurodegenerative diseases such as Alzheimer disease (AD) and cerebrovascular disorders such as vascular dementia (VD). Moreover, many studies highlighted that CBL is effective in the improvement of cognitive impairment in patients with neurodegenerative diseases. However, the underlying neuroprotective effects of CBL against the VD neuropathology were not fully elucidated. Thus, this review aims to discuss the possible therapeutic efficacy of CBL in the management of VD. In conclusion, CBL could be effective therapeutic strategy in preventing and treating VD by targeting neuroinflammation, BBB injury, and chronic cerebral hypoperfusion.</p>","PeriodicalId":19142,"journal":{"name":"Neuroscience","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.neuroscience.2025.01.040","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Cerebrolysin (CBL) is a combination of neurotrophic peptides and amino acids derived from pig brains. CBL can cross the blood-brain barrier (BBB) and its biological effect is similar to the effect of endogenous neurotrophic effects. The mechanism of action of CBL is related to the induction of neurogenesis, neuroplasticity, neuroprotection, and neurotrophicity. Therefore, CBL may be effective against the development and progression of neurodegenerative diseases such as Alzheimer disease (AD) and cerebrovascular disorders such as vascular dementia (VD). Moreover, many studies highlighted that CBL is effective in the improvement of cognitive impairment in patients with neurodegenerative diseases. However, the underlying neuroprotective effects of CBL against the VD neuropathology were not fully elucidated. Thus, this review aims to discuss the possible therapeutic efficacy of CBL in the management of VD. In conclusion, CBL could be effective therapeutic strategy in preventing and treating VD by targeting neuroinflammation, BBB injury, and chronic cerebral hypoperfusion.

查看原文本刊更多论文

脑溶素在血管性痴呆管理中的可能作用：利用概念。

脑溶素（CBL）是从猪脑中提取的神经营养肽和氨基酸的组合。CBL可穿过血脑屏障（BBB），其生物学效应类似于内源性神经营养效应。CBL的作用机制与诱导神经发生、神经可塑性、神经保护和神经营养有关。因此，CBL可能对阿尔茨海默病（AD）等神经退行性疾病和血管性痴呆（VD）等脑血管疾病的发生和进展有效。此外，许多研究强调CBL对神经退行性疾病患者认知功能障碍的改善是有效的。然而，CBL对VD神经病理的潜在神经保护作用尚未完全阐明。因此，本文旨在探讨CBL在VD治疗中的可能疗效。综上所示，CBL可作为一种针对神经炎症、血脑屏障损伤和慢性脑灌注不足的有效治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuroscience 医学-神经科学

CiteScore

6.20

自引率

0.00%

发文量

394

审稿时长

52 days

期刊介绍： Neuroscience publishes papers describing the results of original research on any aspect of the scientific study of the nervous system. Any paper, however short, will be considered for publication provided that it reports significant, new and carefully confirmed findings with full experimental details.